title: Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia.
authors.forename: S
authors.initials: S
authors.lastname: Mustjoki
authors.forename: T
authors.initials: T
authors.lastname: Lundán
authors.forename: S
authors.initials: S
authors.lastname: Knuutila
authors.forename: K
authors.initials: K
authors.lastname: Porkka
mesh_terms: D000328:Adult; D000368:Aged; D001549:Benzamides; D001853:Bone Marrow / Q000473:pathology*; D001854:Bone Marrow Cells / Q000378:metabolism; D002871:Chromosome Banding; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D016130:Immunophenotyping; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology*; D008214:Lymphocytes / Q000378:metabolism; D008218:Lymphocytosis / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate